Chronic Obstructive Pulmonary Disease: Clinical, Epidemiological, and Molecular Bases

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 March 2026 | Viewed by 487

Special Issue Editor


E-Mail
Guest Editor
Helios Universitätsklinikum Wuppertal, Department of Internal Medicine, Pulmonology and Infectious Diseases, University of Witten/Herdecke, Witten, Germany
Interests: chronic obstructive pulmonary disease

Special Issue Information

Dear Colleagues,

Chronic obstructive pulmonary disease (COPD) is a globally prevalent, progressive condition characterized by persistent airway obstruction and chronic inflammation. It remains one of the leading causes of morbidity and mortality worldwide, with smoking and exposure to pollutants as key risk factors. Despite advances in research, many aspects of the disease’s pathophysiology, risk factors, and optimal treatment strategies remain unclear, underscoring the need for continued investigation.

This Special Issue aims to address the various facets of COPD through a collection of high-quality research. Clinical studies that explore new diagnostic and therapeutic approaches will be central to this Issue. Epidemiological research examining the risk factors, environmental influences, and regional variations in the prevalence of COPD is equally important. Additionally, molecular studies offering insights into the mechanisms driving disease progression and identifying potential therapeutic targets are highly encouraged.

We welcome original research articles, as well as review and systematic review papers, to provide a comprehensive overview of the current state of COPD research. Special consideration will be given to studies identifying biomarkers for earlier diagnosis and more precise prognostic evaluation. Furthermore, research on innovative therapies and personalized treatment strategies is encouraged, as these could open new paths in managing COPD and improving patient care.

Dr. Josef Yayan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic obstructive pulmonary disease
  • COPD
  • emphysema
  • chronic bronchitis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

12 pages, 859 KiB  
Systematic Review
Intravenous Magnesium Sulphate as an Adjuvant Therapy for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by Taimur Farid, Abdousamad Said Omar, Sijah Varar Kandi, Soja Puthiyara Maliyekal, Tze Quan Tuen, Amrutha Thazhuthedath Vijayan, Lakshmi Sudhir Pillai, Ahmed Talaat Deiab, Muhammad Sajid, Ahmad Mesmar, Eman Ibrahim Elzain Hassan, Rijas Keethadath, Hasan Al Chalabi, Tallal Mushtaq Hashmi, Mushood Ahmed and Raheel Ahmed
Life 2025, 15(6), 973; https://doi.org/10.3390/life15060973 - 18 Jun 2025
Viewed by 150
Abstract
Background: Intravenous magnesium sulfate (IV MgSO4) may serve as an effective adjunct therapy to improve clinical outcomes in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). Methods: A comprehensive search was conducted on PubMed, Cochrane, and EMBASE [...] Read more.
Background: Intravenous magnesium sulfate (IV MgSO4) may serve as an effective adjunct therapy to improve clinical outcomes in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). Methods: A comprehensive search was conducted on PubMed, Cochrane, and EMBASE from inception to April 2025 to find eligible studies comparing IV MgSO4 plus standard treatment versus standard treatment alone. A random-effects meta-analysis was conducted using RevMan. Results: Nine studies (seven RCTs and two observational studies) met the inclusion criteria. Pooled analysis demonstrated that adjunctive IV MgSO4 significantly improved peak expiratory flow rate at 45 min (MD = 18.50, 95% CI = 6.36 to 30.65) and significantly reduced hospital admission rates from the emergency department (OR = 0.45, 95% CI = 0.23 to 0.88). No significant differences were observed in the length of hospital stay (MD = −0.83, 95% CI = −2.99 to 1.33) and adverse events (OR = 0.79, 95% CI = 0.20 to 3.13; p = 0.73, I2 = 25%) between the two groups. Conclusions: Adjunct MgSO4 in AECOPD is associated with significant improvement in peak expiratory flow rate at 45 min and reduced hospitalization rates. Additional large-scale, multicenter randomized controlled trials are needed to validate and strengthen these findings. Full article
Show Figures

Figure 1

Back to TopTop